CUBIST PHA(NSDQ:CBST)
|
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN, the first antibiotic in a new class of antiinfectives called lipopeptides. The Cubist product pipeline includes our lipopeptide program and our natural products screening program. Cubist is headquartered in Lexington, MA.
|
# Employees: 489
|
|
Address: 65 Hayden Avenue,Lexington,MA,USA
|
|
Phone: 781 860-8660
|
Fax: 781 861-0566
|
|
Website: www.cubist.com
|
Email: ir@cubist.com
|
Sector: Medical
|
Industry: MED-DRUGS
|
Executive Officers
Dividend
Ex-Dividend Date: N/A
Annual Dividend: N/A
Current Dividend Yield: N/A
Dividend Paid (3 months): N/A
Indicated Dividend: N/A
Earnings
|
Last Earnings Date: 9/30/2008
|
|
Next Earnings Date(Expected): 1/22/2009
|
|
Mean EPS (Next Qtr): $0.34
|
|
Mean EPS (Year): $1.71
|
|
Mean Estimate(Long Term): $29.33
|
|
P/E Ratio(Based on EPS estimate): 14.170
|
|
Number of Estimates: 10
|
|
Shares Performance
|
Period
|
CBST
|
Compare to S&P
|
| YTD |
0.46 %
|
0.51 %
|
| 4 Weeks |
6.78 %
|
1.52 %
|
| 12 Weeks |
21.41 %
|
29.63 %
|
Shares Information
|
Analyst Coverage: Y
|
Avg Volume: 828388
|
|
Shares Outstanding: 56M
|
Market Cap: $1.38B
|
| 52 Week High: $27.98
|
52 Week Low: $16.95
|
| P/E Ratio: 19.730
|
PEG Ratio: 0.480
|
|
Split: On 1/1/1990 CBST split by factor of 2.000
|
Earnings Performance
EPS Growth in Last Quarter: 29.41 %
EPS Growth in Last Year: 37.50 %
Sales Growth in Last Quarter: 10.48 %
Sales Growth in Last Quarter: 40.90 %
Financials
|
Qtr Book Value: $9.32
|
|
Cash Flow/Share: $22.48
|
|
Change in Payout Ratio: -0.010
|
|
Price/Sales: -0.010
|
|
